Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 516

Drug Profile

CX 516

Alternative Names: 1-BCP; Ampakine CX 516; AMPAlex; BDP-12; SPD 420

Latest Information Update: 14 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cortex Pharmaceuticals
  • Class Piperidines
  • Mechanism of Action AMPA receptor agonists; AMPA receptor antagonists; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Autistic disorder; Mild cognitive impairment; Schizophrenia; Sleep disorders; Stroke

Most Recent Events

  • 11 Oct 2004 Two studies have been added to the adverse events and Psychotic disorders therapeutic trials sections ,
  • 01 Jul 2004 Phase-II clinical trials in Sleep disorders in USA (unspecified route)
  • 20 Feb 2004 Data from a media release have been added to the Alzheimer's disease and Cognitive disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top